We advised SOPHiA GENETICS on its IPO, Nasdaq listing and concurrent private placement

Davis Polk advised SOPHiA GENETICS SA on its SEC-registered initial public offering of 13,000,000 ordinary shares for total gross proceeds of $234 million and its private placement of 1,111,111 ordinary shares for total gross proceeds of $20 million. SOPHiA GENETICS SA is listed on the Nasdaq Global Select Market under the ticker symbol “SOPH.”

SOPHiA GENETICS SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM Platform and related solutions, products and services are currently used by more than 780 hospital, laboratory and biopharma institutions globally.

The Davis Polk capital markets team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associates David Li and Jakub P. Jozwiak. Partner David R. Bauer and associates Jesse L. Hallock and Brette L. Trost provided intellectual property advice. Partner Kyoko Takahashi Lin and associate James (Chih-Kai) Lin provided executive compensation advice. Partner Mario J. Verdolini provided tax advice. All members of the Davis Polk team are based in the New York office.